公开(公告)号：WO1994004922A1

公开(公告)日：1994-03-03

申请号：PCT/US1993007287

申请日：1993-08-03

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LENNARTZ, LIESELOTTE ,  MICHEL, Gerd ,  METHTA, Smriti, U. ,  TASKAR, Suhas ,  CLEMENS, John, M. ,  MIMMS, Larry, T. ,  CHAU, Kurt, H. ,  VALLARI, David, S.

IPC: G01N33/576

CPC classification number: G01N33/5767 ,  G01N2800/52

Abstract: A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.

Abstract translation: 用于确定感染丙型肝炎病毒（HCV）并正在接受此类治疗的个体中干扰素治疗的有效性的方法。 监测抗HCV IgM和/或抗GOR IgG的水平提供了确定受感染的患者是否响应干扰素治疗的手段; 这种监测对于诊断为慢性急性HCV感染的患者特别有用。

公开(公告)号：WO1993020445A1

公开(公告)日：1993-10-14

申请号：PCT/US1992002523

申请日：1992-03-31

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  TASKAR, Suhas ,  CLEMENS, John, M. ,  MIMMS, Larry, T. ,  CHAU, Kurt, H. ,  VALLARI, David, S.

IPC: G01N33/563

CPC classification number: G01N33/5767 ,  G01N33/54393

Abstract: An assay for determining the presence of HCV IgM in a test sample. A test sample is contacted with at least one HCV antigen, incubated to form antigen/antibody complexes, and then contacted with an indicator reagent in order to produce a detectable signal. The amount of HCV IgM present in the test sample is proportional to the signal generated. The assay also can include the step of contacting the complexes with an enhancer compound prior to the use of an indicator reagent. Also provided is a test kit useful for performing the assay of the invention.

Abstract translation: 用于确定测试样品中HCV IgM存在的测定法。 将测试样品与至少一种HCV抗原接触，孵育形成抗原/抗体复合物，然后与指示剂试剂接触以产生可检测的信号。 测试样品中存在的HCV IgM的量与产生的信号成比例。 该测定还可以包括在使用指示剂试剂之前使复合物与增强剂化合物接触的步骤。 还提供了可用于进行本发明的测定的测试试剂盒。

公开(公告)号：EP0656116A1

公开(公告)日：1995-06-07

申请号：EP93919871.0

申请日：1993-08-03

Applicant: ABBOTT LABORATORIES

Inventor： LENNARTZ, LIESELOTTE ,  MICHEL, Gerd ,  METHTA, Smriti, U. ,  TASKAR, Suhas ,  CLEMENS, John, M. ,  MIMMS, Larry, T. ,  CHAU, Kurt, H. ,  VALLARI, David, S.

IPC: A61K39 ,  C12N15 ,  C12Q1 ,  G01N33

CPC classification number: G01N33/5767 ,  G01N2800/52

Abstract: A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.

公开(公告)号：EP0634017A1

公开(公告)日：1995-01-18

申请号：EP92910597.0

申请日：1992-03-31

Applicant: ABBOTT LABORATORIES

Inventor： TASKAR, Suhas ,  CLEMENS, John, M. ,  MIMMS, Larry, T. ,  CHAU, Kurt, H. ,  VALLARI, David, S.

IPC: G01N33

CPC classification number: G01N33/54393 ,  G01N33/5767

Abstract: An assay for determining the presence of HCV IgM in a test sample. A test sample is contacted with at least one HCV antigen, incubated to form antigen/antibody complexes, and then contacted with an indicator reagent in order to produce a detectable signal. The amount of HCV IgM present in the test sample is proportional to the signal generated. The assay also can include the step of contacting the complexes with an enhancer compound prior to the use of an indicator reagent. Also provided is a test kit useful for performing the assay of the invention.